scholarly journals Prognostic value of growth differentiation factor-15 in Chinese patients with heart failure: A prospective observational study

2013 ◽  
Author(s):  
Hua Wang ◽  
Qingyong Chen ◽  
Yingying Li ◽  
Xianchao Jing ◽  
Jiefu Yang
Keyword(s):  
Heart Failure ◽  
Observational Study ◽  
Prognostic Value ◽  
Prospective Observational Study ◽  
Chinese Patients ◽  
Growth Differentiation Factor 15 ◽  
Differentiation Factor ◽  
Patients With Heart Failure

Prognostic value of galectin-3 on admission in Chinese patients with heart failure: a prospective observational study

2017 ◽  
Vol 72 (2) ◽  
pp. 188-195 ◽  
Author(s):  
Hua Wang ◽  
Qingyong Chen ◽  
Yingying Li ◽  
Xianchao Jing ◽  
Tianya Liang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Observational Study ◽  
Prognostic Value ◽  
Prospective Observational Study ◽  
Chinese Patients ◽  
Patients With Heart Failure ◽  
Galectin 3

scholarly journals Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure

2021 ◽  
Author(s):  
Abhinav Sharma ◽  
Stephen Greene ◽  
Muthiah Vaduganathan ◽  
Marat Fudim ◽  
Andrew P. Ambrosy ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Outcomes ◽  
Growth Differentiation Factor 15 ◽  
Differentiation Factor ◽  
Patients With Heart Failure

scholarly journals Vasoresponsiveness in patients with heart failure (VASOR): protocol for a prospective observational study

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Marieke E. van Vessem ◽  
Saskia L. M. A. Beeres ◽  
Rob B. P. de Wilde ◽  
René de Vries ◽  
Remco R. Berendsen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Surgery ◽  
Cardiopulmonary Bypass ◽  
Observational Study ◽  
Vascular Reactivity ◽  
Prospective Observational Study ◽  
Ex Vivo ◽  
Phase 1 ◽  
Resistance Arteries ◽  
Patients With Heart Failure

Abstract Background Vasoplegia is a severe complication which may occur after cardiac surgery, particularly in patients with heart failure. It is a result of activation of vasodilator pathways, inactivation of vasoconstrictor pathways and the resistance to vasopressors. However, the precise etiology remains unclear. The aim of the Vasoresponsiveness in patients with heart failure (VASOR) study is to objectify and characterize the altered vasoresponsiveness in patients with heart failure, before, during and after heart failure surgery and to identify the etiological factors involved. Methods This is a prospective, observational study conducted at Leiden University Medical Center. Patients with and patients without heart failure undergoing cardiac surgery on cardiopulmonary bypass are enrolled. The study is divided in two inclusion phases. During phase 1, 18 patients with and 18 patients without heart failure are enrolled. The vascular reactivity in response to a vasoconstrictor (phenylephrine) and a vasodilator (nitroglycerin) is assessed in vivo on different timepoints. The response to phenylephrine is assessed on t1 (before induction), t2 (before induction, after start of cardiotropic drugs and/or vasopressors), t3 (after induction), t4 (15 min after cessation of cardiopulmonary bypass) and t5 (1 day post-operatively). The response to nitroglycerin is assessed on t1 and t5. Furthermore, a sample of pre-pericardial fat tissue, containing resistance arteries, is collected intraoperatively. The ex vivo vascular reactivity is assessed by constructing concentrations response curves to various vasoactive substances using isolated resistance arteries. Next, expression of signaling proteins and receptors is assessed using immunohistochemistry and mRNA analysis. Furthermore, the groups are compared with respect to levels of organic compounds that can influence the cardiovascular system (e.g. copeptin, (nor)epinephrine, ANP, BNP, NTproBNP, angiotensin II, cortisol, aldosterone, renin and VMA levels). During inclusion phase 2, only the ex vivo vascular reactivity test is performed in patients with (N = 12) and without heart failure (N = 12). Discussion Understanding the difference in vascular responsiveness between patients with and without heart failure in detail, might yield therapeutic options or development of preventive strategies for vasoplegia, leading to safer surgical interventions and improvement in outcome. Trial registration The Netherlands Trial Register (NTR), NTR5647. Registered 26 January 2016.

scholarly journals Plasma Growth Differentiation Factor-15 as a Prognostic Biomarker in Children with Congestive Heart Failure

2020 ◽  
pp. 34-42
Author(s):  
Abrar Mohamed Khayal ◽  
Shimaa Basyoni El- Nemr ◽  
Hesham Ahmed El- Serogy ◽  
Amr Mohamed Zoair
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Plasma Level ◽  
Plasma Levels ◽  
Prognostic Value ◽  
Control Group ◽  
Healthy Children ◽  
Growth Differentiation Factor 15 ◽  
Differentiation Factor ◽  
Echocardiographic Assessment

Aim and Objectives: This study aimed to evaluate the plasma levels of Growth Differentiation Factor-15 (GDF-15) in children with congestive heart failure, also to evaluate the diagnostic and prognostic value of this novel biomarker in pediatric congestive heart failure, by correlation of its levels with the clinical status and the echocardiographic data of these patients. Subjects and Methods: This study was conducted on Thirty (30) children with congestive heart failure (CHF), Patients were selected from those admitted to Pediatric Cardiology Unit, Pediatric Department, Tanta University Hospital, from (August 2018-April 2020), and thirty (30) healthy children, matched for age and sex, were enrolled as a control group. All children in this study were subjected to Plain X-ray chest and heart: Cardiothoracic ratio (CTR) was measured, and Echocardiographic assessment: Doppler and Two-dimensional, M-mode Echocardiographic evaluation of these parameters and Plasma level of Growth Differentiation Factor-15 (GDF-15) was measured.   Results: the results revealed that The best cutoff point of GDF-15 to differentiate between cases with CHF and control group was >446.5 ng/l with 93.33% sensitivity, 90% specificity, 90.3% PPV, 93.1% NPV and AUC was 0.992. There was significant decrease of EF% and FS% (systolic dysfunction of LV) in patients with CHF as compared to control group. There was statistically significant positive correlation between plasma level of GDF-15 and Ross clinical stage of CHF. There was statistically significant negative correlation between GDF-15 and EF%, FS % by echocardiography. Conclusion: Plasma levels of GDF-15 were elevated in children with CHF, and these levels were correlated to the Ross staging of CHF and echocardiographic assessment of LV function. Plasma levels of GDF-15 were elevated in patients with bad prognosis, denoting its prognostic value as a novel biomarker in pediatric CHF.

Sign in / Sign up

Export Citation Format

Share Document